Investigational drug · Phase 2
HS-10374
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Psoriasis.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 13, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "HS-10374"
First trial start
2025
Apr 9, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-10374", any sponsor or status.
Conditions studied
As listed on its trial records.
- Psoriasis
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-10374" as an intervention, largest first.
- A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque PsoriasisPivotal-lookingStatus unknown
Hansoh BioMedical R&D CompanyIndustry
NCT06672393 · 375 participants (planned) · Start Nov 4, 2024 · Primary completion Oct 22, 2025
Drug: HS-10374 6mg tablets; HS-10374-matched placebo tablets · For: Psoriasis
Sites: Shanghai, China
- A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque PsoriasisPivotal-lookingNot yet recruiting
Hansoh BioMedical R&D CompanyIndustry
NCT06926582 · 305 participants (planned) · Start Apr 9, 2025 · Primary completion Jul 9, 2026
Drug: HS-10374 6mg tablets; HS-10374-matched placebo tablets · For: Psoriasis
Sites: Shanghai, China
- Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic ArthritisPivotal-lookingStatus unknown
Hansoh BioMedical R&D CompanyIndustry
NCT06176508 · 160 participants (planned) · Start Feb 26, 2024 · Primary completion Apr 28, 2026
Drug: HS-10374; HS-10374-matched placebo tablets and 1 more · For: Psoriatic Arthritis
Sites: Shanghai, China
- A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque PsoriasisPivotal-lookingStatus unknown
Hansoh BioMedical R&D CompanyIndustry
NCT06077331 · 120 participants (planned) · Start Sep 28, 2023 · Primary completion Jul 31, 2024
Drug: HS-10374 tablets 1mg; HS-10374 tablets 5mg and 1 more · For: Psoriasis
Sites: Shanghai, China
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06033742 · 84 participants · Start Nov 13, 2021 · Primary completion Mar 24, 2023
Drug: HS-10374 tablets; HS-10374-matched placebo tablets · For: Psoriasis
Sites: Shanghai, China
Hansoh BioMedical R&D CompanyIndustry
NCT07181343 · 18 participants · Start May 28, 2025 · Primary completion Jun 17, 2025
Drug: HS-10374 tablets; Drospirenone and Ethinyl Estradiol tablets · For: Psoriasis (PsO)
Sites: Qingdao, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Psoriasis
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- AK111Phase 32 trials
Akeso · Psoriasis, Skin Diseases, Ankylosing Spondylitis
- IBI112Phase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriasis
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- CMAB015Phase 31 trial
Taizhou Mabtech Pharmaceutical Co.,Ltd · Psoriasis
- HPP737Phase 31 trial
Newsoara Biopharma Co., Ltd. · Psoriasis
- LZM012Phase 31 trial
Livzon Pharmaceutical Group Inc. · Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.